Daegu, South Korea

So Yeon Kim

USPTO Granted Patents = 5 

 

Average Co-Inventor Count = 3.7

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2018-2025

Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: So Yeon Kim: Innovator in Medical Chemistry

Introduction

So Yeon Kim is a prominent inventor based in Daegu, South Korea. She has made significant contributions to the field of medical chemistry, particularly in the development of compounds used in MRI technology and hair loss treatments. With a total of 5 patents, her work has garnered attention for its innovative approaches to solving medical challenges.

Latest Patents

Among her latest patents, So Yeon Kim has developed a gadolinium-based compound, a method for producing the same, and an MRI contrast agent containing this compound. This invention relates to a gadolinium-based compound represented by a specific chemical formula, which includes linking groups and a Rose Bengal-derived part. Additionally, she has created a peptide aimed at preventing or treating hair loss. This peptide promotes the growth of individual hair follicle cells and increases the amount of hair growth-related cytokines, making it effective for treating alopecia.

Career Highlights

Throughout her career, So Yeon Kim has worked with notable organizations such as Sylus Co., Ltd. and the Daegu Gyeongbuk Institute of Science and Technology. Her experience in these institutions has allowed her to refine her research and contribute to advancements in medical technology.

Collaborations

So Yeon Kim has collaborated with esteemed colleagues, including Che Il Moon and Seung Jun Yoo. These partnerships have facilitated the exchange of ideas and fostered innovation in her projects.

Conclusion

In summary, So Yeon Kim is a trailblazer in the field of medical chemistry, with a focus on developing innovative solutions for MRI technology and hair loss treatments. Her contributions continue to impact the medical community positively.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…